Pfizer Inc: Pfizer submits data showing Covid-19 vaccine’s stability in refrigerators


Pfizer Inc and companion BioNTech SE mentioned on Friday they’ve submitted new data to the U.S. well being regulator showing the stability of their COVID-19 vaccine at temperatures generally discovered in pharmaceutical freezers and refrigerators.

Pfizer/BioNTech’s vaccine, together with Moderna Inc’s two-dose vaccine, received the U.S. emergency use authorization (EUA) and is being broadly distributed as a part of the nation’s mass vaccination efforts.

If authorised, the much less onerous storage necessities would offer a giant logistical reduction as a result of the vaccine for now must be saved at minus 70 levels Celsius for longer durations, a problem notably in lower-income nations that do not have the ultra-cold-storage infrastructure.

Pfizer/BioNTech’s present label requires the vaccine to be saved in an ultra-cold freezer at temperatures between -80oC and -60oC (-112oF to -76oF), calling for it to be shipped in specifically designed containers.

The corporations mentioned the brand new data has been submitted to the U.S. Food and Drug Administration to help a proposed replace to the present EUA label, which might enable for vaccine vials to be saved at -25°C to -15°C (-13°F to five°F) for a complete of two weeks in its place for storage in an ultra-low temperature freezer.

This feed is robotically printed by way of